Voyageur Pharmaceuticals Ltd. Announces Two Health Canada Approvals and Issuance of Product Licenses for MultiX Ba; Radiographic Barium Contrast

April 06 11:06 2021

Calgary, Alberta – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiX barium sulfate powder. MultiX is specifically designed for oral suspension and indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract in adult and pediatric patients. Voyageur received 2 licenses for MultiX, one license for oral applications and one license for rectal applications.

Voyageur is building a suite of barium radiographic contrast media products and is working with our custom manufacturer, Alberta Veterinarian Laboratories (AVL), which company owns and operates a brand new, multi-million dollar, state-of-the-art, Good Manufacturing Practice (GMP) drug manufacturing facility in Calgary, Alberta, Canada. Voyageur is rapidly moving to launch its sales into the Canadian and international market places.

With three drugs now approved and licensed by Health Canada and two more in the offing, Voyageur is shortly hiring highly-experienced radiographic contrast media professionals to our team to support:

• Scientific research and development to capitalize on opportunities to expand our high-quality barium and iodine contrast product portfolio into global markets.

• International marketing, sales and distribution.

Marketing and Sales Strategy 2021

Approval timelines and high profit margin are the criteria for Voyageur’s international sales strategy. Voyageur is actively analyzing international markets, where recognition of Voyageur’s Health Canada registrations is anticipated to assist Voyageur in obtaining licenses in an expeditious manner. Upon conclusion of our analysis, Voyageur will begin applying for registration applications on a country-by-country basis, including FDA licenses in the USA.

Voyageur is working with AVL and is preparing to test our newly-formulated products under GMP and HC guidelines. Upon conclusion of testing, phase one marketing is expected to begin followed by sales and distribution to the Canadian, USA and international markets.

Fiscal 2020 Year End

Voyageur is also pleased to announce that the fiscal 2020 year-end Management Discussion and Analysis and audited Financial Statements have been filed and uploaded to SEDAR.

About Voyageur

Voyageur Pharmaceuticals Ltd. is Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite and iodine, Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium and iodine radio-contrast pharmaceutical products. Voyageur’s goal is to initially generate near term positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing. Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, with interests in a potentially high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field, by controlling all primary input costs under the motto of: “From the Earth to the Bottle”

For Further Media Information or to set up an interview, please contact:

Brent Willis
President & CEO
E: [email protected]

Ron Love
T: 403.818.6086
E: [email protected]

Forward Looking Information

This news release may contain certain forward-looking information and statements, including, without limitation, statements pertaining to commercial launch of its products, including timing for manufacturing and sales of MultiX Ba, anticipated marketing and sales plans, and the expected timing thereof, the ability to obtain licenses in international jurisdictions, and to do so expeditiously based on existing HC approvals, and the Company’s ability to obtain necessary approvals from Health Canada for additional barium radiographic contrast products. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Reader Advisory

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Media Contact
Company Name: Voyageur Pharmaceuticals Ltd
Contact Person: Brent Willis
Email: Send Email
City: Calgary
State: Alberta
Country: Canada